Patients with severe COVID-19 requiring intubation and mechanical ventilation
Care Setting
Medical intensive care unit in an academic hospital
Key Highlights
Higher plasma ceramide levels (C16, C22, C24) observed in nonsurvivors during the first week of illness, followed by lower levels in subsequent weeks compared to survivors.
Ceramide temporal trajectories inversely correlated with traditional inflammatory markers (CRP, ESR, D-dimer, ferritin), resembling negative acute-phase reactants.
Ceramide species behavior in acute COVID-19 differs from chronic disease patterns, suggesting disease acuity influences ceramide dynamics.
Guideline-Based Recommendations
Diagnosis
Measure plasma ceramide species (C16, C22, C24) alongside standard inflammatory markers in severe COVID-19 patients to assess prognosis.
Management
Consider monitoring ceramide levels as potential prognostic biomarkers to guide clinical decision-making in severe COVID-19.
Monitoring & Follow-up
Obtain serial plasma ceramide measurements weekly from symptom onset up to 6 weeks to observe temporal trends related to outcomes.
Risks
Elevated C16 ceramide levels early in disease may indicate higher risk of mortality.
Altered ceramide flux may reflect dysregulated inflammatory response contributing to disease severity.
Patient & Prescribing Data
Severe COVID-19 patients requiring mechanical ventilation
Nonsurvivors more frequently received convalescent plasma; ceramide levels may provide additional prognostic information beyond current treatments.
Clinical Best Practices
Incorporate plasma ceramide profiling in research and potentially clinical protocols for severe COVID-19 to improve prognostic accuracy.
Interpret ceramide levels in conjunction with traditional inflammatory markers due to their inverse relationship.
Recognize that ceramide species have distinct roles and temporal patterns in acute COVID-19 compared to chronic diseases.
